» Articles » PMID: 29514700

Impact of a Genetic Counseling Requirement Prior to Genetic Testing

Overview
Publisher Biomed Central
Specialty Health Services
Date 2018 Mar 9
PMID 29514700
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Genetic counseling by a Genetic Counselor (GC) is a requirement prior to genetic testing for cancer susceptibility genes (GC-mandate policy) for some insurers. This study evaluated the impact of this policy from the patient perspective.

Methods: Surveys were sent to individuals for whom their insurer ordered genetic testing for the cancer susceptibility genes BCRA1 and BRCA2 over a 1 year time period that spanned the introduction of a GC-mandate policy. Responses were assessed by time period (before/after policy introduction) and genetic test completion.

Results: The surveys were completed by 1247/4950 (25.7%) eligible individuals. After policy introduction, there was no change in the proportion of respondents who completed genetic testing (p = 0.13) or had a mutation (p = 0.55). Overall decisional conflict (uncertainty or feeling uninformed) around genetic testing did not change after policy introduction (p = 0.16), but was significantly higher among respondents who did not complete genetic testing (p < 0.01). Although a larger proportion of respondents saw a GC after policy introduction (p < 0.01), fewer did so to better understand their test results (p < 0.01). The proportion of respondents who did not see a GC due to insurance issues/requirements and time restraints was higher among those tested after policy introduction or who did not complete genetic testing (p < 0.01). In multivariate analysis, respondents with a household income of $25,000 or greater were 3-times more likely to complete testing.

Conclusions: A GC-mandate policy did not improve decisional conflict or increase the number of deleterious mutations identified and low-income respondents were less likely to complete testing. On the contrary, insurance requirements and time constraints may be preventing individuals at risk from receiving appropriate testing.

Citing Articles

Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.

Rosso C, Marciano N, Nathan D, Chen W, McLaren C, Osann K J Natl Compr Canc Netw. 2024; 22(5):299-305.

PMID: 38889755 PMC: 11462954. DOI: 10.6004/jnccn.2023.7333.


Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With -ALS.

Morganroth J, Bardakjian T, Dratch L, Quinn C, Elman L Neurol Clin Pract. 2024; 14(4):e200303.

PMID: 38855716 PMC: 11157423. DOI: 10.1212/CPJ.0000000000200303.


The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient.

Schick S, Manghelli J, Ludwig K Curr Oncol. 2023; 30(5):4677-4687.

PMID: 37232811 PMC: 10217718. DOI: 10.3390/curroncol30050353.


Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.

Crowley F, Gandhi S, Rudshteyn M, Sehmbhi M, Cohen D Oncologist. 2023; 28(6):486-493.

PMID: 36933202 PMC: 10243789. DOI: 10.1093/oncolo/oyad044.


Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.

Kinney A, Walters S, Lin Y, Lu S, Kim A, Ani J J Clin Oncol. 2023; 41(15):2767-2778.

PMID: 36787512 PMC: 10414736. DOI: 10.1200/JCO.22.00751.


References
1.
Kaplan C, Livaudais-Toman J, Tice J, Kerlikowske K, Gregorich S, Perez-Stable E . A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomarkers Prev. 2014; 23(7):1245-53. PMC: 4167008. DOI: 10.1158/1055-9965.EPI-13-1380. View

2.
Desai S, Jena A . Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial. BMJ. 2016; 355:i6357. PMC: 5156611. DOI: 10.1136/bmj.i6357. View

3.
. Committee opinion no. 634: Hereditary cancer syndromes and risk assessment. Obstet Gynecol. 2015; 125(6):1538-1543. DOI: 10.1097/01.AOG.0000466373.71146.51. View

4.
Hayden S, Mange S, Duquette D, Petrucelli N, Raymond V . Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling. J Genet Couns. 2017; 26(4):859-865. DOI: 10.1007/s10897-016-0064-5. View

5.
Whitworth P, Beitsch P, Arnell C, Cox H, Brown K, Kidd J . Impact of Payer Constraints on Access to Genetic Testing. J Oncol Pract. 2017; 13(1):e47-e56. DOI: 10.1200/JOP.2016.013581. View